Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults With Mild to Moderate Knee Osteoarthritis

Knee Osteoarthritis Clinical Trial

Official title:

Non-thermal Pulsed Radio Frequency for Pain Amelioration in Adults With Knee Osteoarthritis: A Double-blind, Randomized, Sham-controlled Trial

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01457742
• Other study ID #: Ivivi-OAPain-001
• Status: Terminated
• Phase: Phase 4
• First received: October 19, 2011
• Last updated: July 6, 2012
• Start date: October 2011
• Est. completion date: July 2012

Study information

• Verified date: July 2012
• Source: Amp Orthopedics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of non-thermal Pulsed Radio Frequency (PRF) treatment with the Ivivi SofPulse for amelioration of knee pain in patients with mild to moderate Osteoarthritis and to determine the duration of clinical benefit following discontinuation of treatment.

Description:

This prospective, double-blind, randomized, sham-controlled clinical trial will investigate the effectiveness of PRF using the Ivivi SofPulse on knee pain severity in adults with mild to moderate knee OA. Potential subjects will complete questions related to medical history, inclusion / exclusion criteria, and OA symptom severity. Knee radiographs will be evaluated by the Principal Investigator (PI) or co-investigator for determination of knee OA severity based on the Kellgren/Lawrence criteria. Eligible subjects will enter a 1-week run-in period. After successful completion of the run-in period, subjects will be randomized to PRF treatment twice a day (Active) or sham treatment twice a day (Sham). All subjects will be followed for 4 weeks for purposes of the primary endpoint evaluation. Thereafter, the subjects initially allocated to Active will be equally allocated to Active or Sham and will be followed through 26 or 8 weeks, respectively. The subjects originally assigned to Sham will maintain this treatment regimen through 26 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 45
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Age 40 to 80 years

• Bilateral weight-bearing anteroposterior x-ray of each knee taken within the last 12 months and radiographs submitted to the Principal Investigator for evaluation

• Radiographic evidence of mild to moderate (Kellgren/Lawrence grade 2 or 3) OA in at least one knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months

• Self-reported persistent knee pain severity of 4.0 to 8.0 cm on a 10 cm VAS for most days in the previous 2 months in at least one knee, with grade 2 or 3 OA

• Able to read and complete English-language surveys

• Daily access to the internet

• Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects

• Consent to the study and willing to comply with study methods

Exclusion Criteria:

• Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverterdefibrillator)

• Self-reported persistent knee pain severity > 8.0 cm on a 10 cm VAS in either knee for most days in the previous 2 months

• Radiographic evidence of severe (Kellgren/Lawrence grade 4) OA in either knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months

• Self-reported diagnosis of autoimmune or inflammatory arthritis (e.g. Rheumatoid Arthritis, Lupus, etc.)

• More than 8 days of narcotic pain medication in the last 30 days

• Joint surgery, tidal lavage, or arthroscopy of either knee in the past 6 months

• Intra-articular corticosteroid or hyaluronic acid injections of either knee in the past 6 months

• Oral prednisone use in the past 30 days

• Participation in any clinical trial in the past 30 days

• Knee OA associated with worker's compensation or accident litigation

• Regular use of a walker or wheelchair

• Vulnerable populations including prisoners and nursing home residents

• Anticipated move away from immediate area in next 6 months

• Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness

After 1-week Run-in Period

• Daily average of "current" knee pain severity < 4.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in both knees

• Daily average of "current" knee pain severity > 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in either knee

• Daily average of "current" knee pain severity of 4.0 to 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in any knee with Kellgren/Lawrence grades of 0 or 1 in the same knees

• Narcotic use of more than 2 days during the 1-week runin period

• Noncompliance with online symptom reporting requirements

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

Intervention

Device:
• Ivivi SofPulse
15 minute Pulsed Radio Frequency (PRF) treatment twice per day
• Ivivi SofPulse
15 minute simulated treatment using Sham Device twice per day

Locations

Country	Name	City	State
United States	Mytrus, Inc.	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
Amp Orthopedics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	A comparison of changes in VAS pain scores at 4 weeks over baseline.	Comparison of changes in "current" knee pain severity at 4 wks over baseline. Between-group difference of at least 25 percentage points considered clinically significant. "Current" knee pain severity assessed on a 10 cm visual analogue scale, 0 (no pain) and 10 (pain as bad as it can be). The knee that meets radiographic criteria for mild or moderate knee OA and has the highest knee pain severity based on the average daily severity score during the 1-wk run-in period will be selected for the primary endpoint analysis.	Four weeks	No
Secondary	Change in knee pain severity and duration of clinical benefit following treatment.	"Maximum" knee pain severity assessed on a 10 cm VAS and pain improvement	Four weeks	No
Secondary	EuroQol EQ-5D	Improvement of quality of life	Four weeks	No
Secondary	OMERACT-OARSI Responder Rate	Change in need of pain medications and modalities due to knee pain	Four weeks	No
Secondary	Adverse events	Occurance of Adverse Events during treatment period	Four weeks	No
Secondary	Treatment compliance	Improvement of pain and decrease in pain medication with compliant use of the PRF study device as compared to the Sham device.	Four weeks	No

External Links

•   website for Mytrus
•   website for study